^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    LGALS4 expression

    i
    Other names: LGALS4, Galectin 4, GAL4, Lectin, Galactoside-Binding, Soluble, 4, L-36 Lactose-Binding Protein, Lactose-Binding Lectin 4, Antigen NY-CO-27, Galectin-4, L36LBP, Gal-4
    Entrez ID:
    3960
    1year
    LGALS4 inhibits glycolysis and promotes apoptosis of colorectal cancer cells via β‑catenin signaling. (PubMed, Oncol Lett)
    LGALS4 overexpression inhibited CRC cell growth, induced cell cycle arrest and enhanced 5-fluorouracil (5-FU)-induced apoptosis...The downregulatory effect of LGALS4 on glycolysis-related genes was further enhanced by the addition of the β-catenin inhibitor XAV-939...Overexpression of LGALS4 reduced the proliferation and glycolytic capacity of CRC cells and also enhanced their sensitivity to 5-FU. These results may potentially provide new perspectives for CRC treatment and targets for future clinical intervention strategies.
    Journal
    |
    LGALS4 (Galectin 4)
    |
    LGALS4 expression
    |
    5-fluorouracil • XAV-939
    over2years
    Galectin-4 Is Involved in the Structural Changes of Glycosphingolipid Glycans in Poorly Differentiated Gastric Cancer Cells with High Metastatic Potential. (PubMed, Int J Mol Sci)
    Furthermore, mass spectrometry (MS) combined with glycosidase digestion revealed that this structural change was due to the presence of the lacto-type (β1-3Galactosyl) glycan of GSL, in addition to the neolacto-type (β1-4Galactosyl) glycan of GSL. Our results demonstrate that galectin-4 is an important regulator of glycosylation in cancer cells and galectin-4 expression affects the glycan profile of GSLs in malignant cancer cells with a high potential for peritoneal dissemination.
    Journal • Metastases
    |
    LGALS4 (Galectin 4)
    |
    LGALS4 expression